From Financing to Exit: What's New for Life Sciences Companies? | McDermott Skip to main content

From Financing to Exit: What’s New for Life Sciences Companies?

From Financing to Exit: What’s New for Life Sciences Companies?

Overview


Programme

17.00 Registration
17.30 Panel discussion
19.00 Cocktail Reception

McDermott is pleased to invite you to a panel discussion to be held in our Paris office on May 23, immediately post-BioEquity – see our panel of outside experts listed below. Also, we have selected financing/exit specialists from McDermott’s BioEquity Team to be present for informal commentary.

Introduction

Emmanuelle Trombe, Partner, McDermott Will & Emery Paris

SPEAKERS

Rafaele Tordjman, Special Advisor, Sofinnova

Cédric Moreau, Managing Director, Oddo

Glyn Edwards, Chief Executive Officer, Summit Therapeutics plc

Jacky Vonderscher, Ph.D, Chief Executive Officer, Enyo Pharma SA

Paul Hadden, Managing Director, HealthCare Royalty Partners

Mark Selinger, Partner, McDermott Will & Emery New York

Kristian Werling, Partner, McDermott Will & Emery Chicago

Dig Deeper

Brussels, Belgium / Speaking Engagements / May 21, 2026

EU Pharmaceutical Law Forum 2026

Webinar / Webinar / February 25, 2026

ISO 13485 Compliance for Medical Device Companies

Paris, France / DeepLife / February 19, 2026

Infinite 2026: Unlocking new value in existing therapies

San Francisco, CA / In-person / January 13, 2026

McDermott Forum at the 2026 J.P. Morgan Healthcare Conference

Dallas, TX / In-person / December 4, 2025

Health Innovators Holiday Celebration 2025